#+OPTIONS: org-inline-image-overlays:t org-image-actual-width:20 tex:t toc:t H:9
#+STARTUP: latexpreview
#+ATTR_HTML: :width 40px
* fluids and electrolytes
** normal electrolyte values
*** Sodium
136 mEq/L – 145 mEq/L
*** Potassium
3.5 mEq/L – 5 mEq/L
*** Magnesium
1.7 mg/dL – 2.3 mg/dL
*** Calcium
8.5 mg/dL – 10.5 mg/dL
*** Phosphorus
2.5 mg/dL – 4.5 mg/dL
** crystalloids and colloids
*** crystalloids
- NS
- LR
**** distribution in fluid compartments
**** risks
**** benefits
- less costly
- fewer ADRs
*** colloids
- albumin
- hydroxyethyl starch / hetastarch (HES)
- dextran
**** distribution in fluid compartments
25% albumin: intravascular; 5000 mL
**** risks
**** benefits
** fluid requirements
*** maintenance
- adults: 30-40 mL/kg
- pediatrics: “4, 2, 1” rule
  - 4 mL/kg/hr + 2 mL/kg/hr * (weight > 10kg) + 1 mL/kg/hr * max(0, weight - 20 kg)
  - first 10 kg: 4 mL/kg/hr
  - second 10 kg: 2 mL/kg/hr
  - thereafter: 1 mL/kg/hr
*** water deficit
**** male
\( 0.6 * \mathit{IBW} * \frac{sNa}{140} - 1 \)
**** female
\( 0.5 * \mathit{IBW} * \frac{sNa}{140} - 1 \)
** hyponatremia
*** treatment
**** pharmacological
- lithium
- fludrocortisone
- Tolvaptam (Samsca)
- Conivaptan (Vaprisol)
**** non-pharmacological
** hypokalemia
*** drug-induced
transcellular shift:
- insulin
- β agonists
- alkalosis, anything that causes
enhanced renal excretion:
- diuretics
laxatives:
- Sodium polystyrene sulfonate (Kayexalate)
- Sodium zirconium cyclosilicate (Lokelma)
- Patiromer (Veltassa)
* shock
** exam :ignore:
** definition
acute state characterized by inadequate perfusion of critical organs; can produce serious consequences including death
SBP ≤90 mm Hg + end organ damage
*** types of shock
- cardiogenic
- hypovolemic
- anaphylactic
- septic
- neurogenic
*** stages of shock
- initial
- compensatory (warm)
- progressive (cold)
- refractory
*** MAP
\begin{equation}
\frac{2*\mathit{DBP} + \mathit{SBP}}{3}
\end{equation}
** causes
- hypovolemia
- cardiogenic
- distributive
** end organ damage :l:
*** brain
**** labs
- abnormal CT scan
- abnormal MRI
- abnormal EEG
*** heart
**** labs
- elevated troponins (reference: <0.6 ng/mL)
- reduced ejection fraction on ECHO (<45%)
- elevated BNP (reference: 0-99 pg/mL)
- abnormal EKG—STEMI, NSTEMI
*** kidneys
**** labs
- elevated SCr
- elevated BUN
*** liver
**** labs
- elevated LFTs
- elevated INR
** hemodynamic parameters
*** CO
- volume of blood pumped by the ventricle in 1 minute
- CO = SV × HR
*** Systemic Venous Oxygen Saturation (SVO2)
measure of tissue oxygenation
*** Central Venous Pressure (CVP)
correlates to the amount of blood returning to the heart
*** PCWP
preload
*** SVR
afterload
*** by shock etiology
|              | CO          | CVP  | SVO2        |
|--------------+-------------+------+-------------|
| hypovolemia  | down        | down | down        |
| cardiogenic  | down        | up   | down        |
| distributive | slightly up | down | slightly up |
*** 
** treatment
*** crystalloids :l:
**** normal saline
**** 5% dextrose water (D5W)
**** Lactated Ringer’s solution
*** colloids :l:
**** albumin
***** adverse effects
- leakage into intravascular and interstitial space
- anaphylaxis
- renal toxicity
- hemolysis
**** hydroxyethyl starch
**** dextran
*** side effects
**** crystalloids
- peripheral and pulmonary edema
- for saline: hyperchloremic acidosis
- for dextose: hyperglycemia
- for LR/Plasmalyte: electrolyte abnormalitiees
**** colloids
- cardiac failure
- edema
- for HES: mortality or renal failure
- anaphylaxis
- bleeding
*** fluid resuscitation
isotonic crystalloids:
- NS
- LR
20 mL/kg bolus
*** pressors
**** adverse effects
extravasation; manage with phentolamine subQ, hot/cold compresses, or elevation of affected extremity
**** first line agent
norepinephrine
**** non-first line agents
***** dobutamine
****** MOA
- beta-{1, 2} > alpha-1 receptors
- beta-2 receptor agonist on skeletal muscle
- increases cardiac output
***** vasopressin
****** MOA
activates aquaporins, reabsorbing water
* renal
** exam :ignore:
*** Wong
**** phosphate management
**** phosphate binding agents
**** calciumemtic agent
**** vitamin D maintains Ca homeostasis
**** anemia related to erythrypoietin
**** pharmacokinetic & pharmacodynamic change--general principle of changes in PK & PD changes w.r.t. pharmacotherapy
**** exam 1
***** dobutamine
- beta agonist
- positive ionotropic effect
- pka A activity in heart
  - phosphorylate L type calcium channel
  - phosphorylate ryanodine receptor
    - calcium release from SR
    - ionotropic effect
  - phosphorylate phospholamban (sp?)
    - calcium cycling in the cell
    - increases calcium usage as it's more effective
** chronic renal disease
*** pathophysiology
- anemia
- calcium loss from bone
  - high PTH
  - decreased vitamin D synthesis
- decreased renal elimination
*** treatments :l:
**** phosphate-binding agents
***** MOA
1. form insoluble phosphate compounds in GI tract
2. excretes in feces
**** vitamin D
***** metabolism in organs
****** calcitriol
kidneys
****** calcifediol
liver
****** cholecalciferol
skin
***** rank order of bioavailability
calcitriol > calcifediol >>> cholecalciferol
**** calcimimetics :l:
***** cinaclet
****** brand
Sensipar
****** adverse effects
hypocalcemia
****** interactions
- CYP2D6
  - flecainide
  - thioridazine
  - vinblastine
  - tricyclic antidepressants; esp. amitriptyline
- CYP3A4
  - ketoconazole
****** MOA
1. binds to calcium-sensing receptor (CaSR)
2. increases Ca-CaSR interaction
3. reduce PTH secretion
***** cinacalcet + low dose vitamin D
**** EPO
**** osmotic diuretics
***** drugs :l:
- mannitol
- glycerin
- isosorbide
- urea
***** site of action
proximal convoluted tubule
*** drug-disease interactions
**** NSAIDs
avoid NSAIDs in CKD
**** LMWH
- eGFT <30 mL/min lengthens t_1/2
  - increases anticoagulant anti-10a
  - increases risk of major bleeding
- LMWH excreted by kidneys
**** furosemide
loop diuretics are effective in patients with residual renal function
**** propranolol
decreased clearance because chronic renal failure downregulates CYP450, which normally metabolizes propranolol
*** terminology
**** KDOQI
Kidney Dialysis Outcomes and Quality Initiative
**** KDIGO
Kidney Disease Improving Global Outcomes
**** kidney failure
GFR <15 mL/min/1.73 m²
** acute kidney injury
*** non-pharmacologic therapy
isotonic crystalloids
- normal saline
- LR
*** KDIGO guidelines
**** prevention
- NAC
- sodium bicarbonate
These are also treatments:
- vasopressors
- isotonic saline
**** treatment
- isotonic saline
- RRT
- vasopressors
*** RIFLE criteria
*** acute intrinsic
**** extrinsic toxins
- aminoglycosides
- amphotericin
- IV contrast agents
**** medications exacerbating :ignore:
- penicillins
- cephalosporins
- ciprofloxacin
- NSAIDs
**** diagnostic findings
- urine osmolality similar to plasma osmolality
- “dirty brown casts”
- high Na excretion
**** management
***** medications
- Prednisone 1 mg/kg/d x 1 wk
*** dialysis
**** indications
AEIOU:
- Acid Base Abnormalities
- Electrolyte imbalance
- Intoxications
- fluid Overload
- Uremia
** diabetes insipidus :l:
*** central
*** nephrogenic
*** dipsogenic
*** gestational
** dialysis
*** indications
- Acid Base Abnormalities
- Electrolyte imbalance
- Intoxications
- fluid Overload
- Uremia
** chronic kidney disease
*** lab tests
**** early CKD
- microalbuminuria
- Mildly elevated serum creatinine and blood urea nitrogen
**** late CKD
- proteinuria, persistent
- ↓ GFR
- ↓ CrCl
**** quantification of proteinuria
***** 24 hour collection
- microalbuminuria: 30-300 mg/day
- clinical proteinuria/albuminuria ≥300 mg/day
- normal: <300 mg/day protein
***** albumin:creatinine; spot collection
- microalbuminuria: 30-300 mcg/mg
- clinical proteinuria/albuminuria: >300 mcg/mg
- normal: <30 mcg/mg
**** urinalysis
***** normal pH
4.5-7.8
***** glucose
- functioning kidney doesn’t lose glucose
- normal BG >180 mg/dL
***** protein/albumin
marker of kidney damage
* acid base
** anion gap
*** formula
Na - Cl - HCO₃
*** elevated
**** causes
“MUDPILES” mnemonic:
- Methanol Ingestion
- Uremia
- Diarrhea
- Propylene Glycol
- Isoniazid
- Lactic Acidosis
- Ethylene Glycol
- Salicylates
** alkalosis
* respiratory
** drug classes
*** bronchodilators :l:
**** sympathomimetics
***** direct-acting
****** MOA
- β-agonists
- α-agonists
****** SAR
******* w.r.t [[./phenethylamine.png]]
- at R1 (amino): increase in R1 size increases β receptor selectivity
- at R2 (α carbon):
  - Ethyl group increases β receptor selectivity.
  - Alkylation interferes with MAO metabolism; can still be metabolized by COMT
******* catechol metabolism
resorcinol and salicylic alcohol cannot be metabolized by COMT
****** fundmanetal pharmacophore
substituted β-phenylethylamine
****** classes
******* short acting β-2 agonists (SABAs)
******** drugs
********* albuterol
********** brands
*********** all :ignore:
- Airolin
- Airomir
- Asmasal
- Buventol
- Evohaler
- Inspiryl
- Proventil
- Salamol
- Salbulin
- Ventodisk
- Ventolin
*********** metered dose inhaler (MDI)
- ProAir HFA
- Proventil HFA
- Ventolin HFA
*********** dry powder inhaler (DPI)
ProAir Respiclick
********* levalbuterol
********* pirbuterol
********** brand
Maxair
********* Metaproterenol; Terbutaline
********* Tornalate
********* bambuterol
********** brand
Bambec
********* fenoterol
********** brand
Berotec
********* isoproterenol
********** brand
Isuprel
********* levalbuterol
********** brand
Xopenex
********* Levalbuterol
********** brand
Xopenex
********* Metaproterenol
********** brand
- Alupent
- Metaprel
- ProMeta Maxair
********* Pirbuterol
********** brand
Alupent, Metaprel, ProMeta
********* Isoetherine
********** brand
Bronkosol, Bronkometer
********* Terbutaline
********** brands
- Breathaire
- Brethine
- Bricanyl 
********* Tornalate
********** brand
Bitolerol
******** adverse effects
- tachycardia
- muscle tremors
- dry mouth
- urinary flow obstruction
- increased intraocular pressure
******** MOA
- sympathomimetic
- relaxes airway smooth muscles
******* long acting beta agonists (LABAs) :l:
******** drugs :l:
********* salmeterol
********* formoterol fumarate
******** adverse effects
- arrhythmias
- hyperglycemia
- hypokalemia
******** MOA
sympathomimetic
******** black box warning
LABA increases risk of asthma-related death
***** indirect-acting
****** releasers
****** reuptake inhibitors
***** intracellular target
cAMP signaling
**** antimuscarinic drugs
***** SAR
ionized N is required
***** classes
****** short acting inhaled muscarinic receptor antagonists (SAMAs)
******* drugs :l:
******** ipratropium bromide
********* brand
Atrovent
******** oxitropium bromide
******* adverse effects
- tachycardia
- muscle tremors
****** long acting inhaled muscarinic receptor antagonists (LAMAs)
******* drugs :l:
******** tiotropium
********* brand
Spiriva
******* adverse effects
- arrhythmias
- hyperglycemia
- hypokalemia
**** methyl xanthines
***** structure
[[./xanthine.png]]
***** MOA
- inhibits PDE4
- cAMP isn’t broken down; cAMP causes bronchodilation
***** drugs :l:
****** theophylline
******* brand
Elixophyllin
****** roflumilast
******* brand
Daliresp
******* MOA
- very potent; only 500 µg needed
- PDE4 selective
- safe on heart
***** adverse effect
- emesis/vomiting
- can’t increase the dose because it will cause vomiting
*** anti-inflammatory agents :l:
**** glucocorticosteroids
***** SAR
****** cortisol
******* structure
[[./cortisol_numbered.png]]
******* C-17 oxidation
C-17 oxidation results in a shorter half life
[[./cortisol_C-17_oxidase.png]]
******* C-11
[[./cortisol_numbered.png]]
****** corticosteroids
******* functional groups required for activity
- -OH at C11 and C21
- C=O at C3
- C4=C5
- -OH at C17
******* prodrug
- C=O at C11
- ester at C21
******* increase DOA
- ester or ether at C17
- make prodrug
******* increases glucocorticoid activity, reduces mineralocorticoid activity
- C1=C2
- C16 substitution
- C6 substitution
******* increases both glucocorticoid and mineralocorticoid activity
C9 fluoroidation
***** drugs
****** systemic :l:
******* prednisone
******* methylprednisone
******* dexamethasone
******* hydrocortisone
****** inhaled :L:
******* fluticasone propionate
******** brands :l:
********* Flovent HFA
********** dose
*********** low
176 mcg
*********** high
>440 mcg
********* Advair
********* Flovent Diskus
********** dose
*********** low
200-300 mcg
*********** high
>500 mcg
********* Arnuity Ellipta
********** dose
100-400 mcg (1-2 inh) QD
******* triamcinolone acetonide
******** brand
Azmacort
******* budenoside
******** brand
- Plumicort Flexhaler
- Respules
******* beclomethasone
******** brand
- QVAR
- Beclovent
- Vanceril
******* flunisolide
******** brand
AeroBid
******* mometasone
******** brand
Asmanex {HFA, Twisthaler}
******* ciclesonide
******** brand
Alvesco
***** MOA
- inhibits synthesis of arachidonic acid
- by inhibiting arachidonic acid, glucocorticoids inhibit expression of COX2 and in turn inhibits the synthesis of prostaglandins
***** adverse effects
hypokalemia
**** Mast Cell Degranulation inhibitors
***** drugs :l:
****** cromolyn sodium
****** nedocromil sodium
**** Leukotrine Inhibitors
***** classes :l:
****** lipoxygenase inhibitors :l:
******* Zileuton
******** brand
Zyflo
****** leukotreine receptor inhibitors :l:
******* monteleukast
******** brand
Singulair
******* zafirlukast
******** brand
Accolate
***** MOA
reduces inflammatory response by…
- inhibiting 5-lipoxygenase; prevents arachidonic acid → leukotrienes
- antagonizing LTD4 receptors; blunted contraction of airway smooth muscle cells
**** Anti-IgE monoclonal antibodies
***** MOA
relieves symptoms; Monoclonal antibody inhibits IgE interaction with mast cells and basophils
[[./omalizumab_moa.png]]
***** drugs
****** omalizumab
******* brand
Xolair
** COPD
*** drug classes used
- LAMA
- LABA
- SABA + SAMA
- LAMBA + PDE4 inhibitor
** asthma
*** combination
- FDA requires LABAs to be combined with corticosteroids
- LABAs/corticosteroids are for prophylaxis of asthma, not acute asthma attacks
** congestion
*** short-acting decongestants
α-adrenergic agonists delivered via a nasal spray
**** drugs :l:
***** phenylephrine
***** oxymetazoline
****** brand
Afrin
*** long-acting decongestants
α-adrenergic agonists delivered systemically
**** drugs
***** pseudoephedrine
** dry cough
*** treatment plan
- suppress with antitussives
- treat with expectorants/mucolytics
*** antitussives
**** MOA
depresses cough center in the medulla of the brain
**** drugs :l:
***** dextromethorphan
****** brand
- Benylin
- Robitussin
- Delsym
***** codeine
***** benzonatate
****** brand
Tessalon Perles
*** expectorants/mucolytics
**** drugs :l:
***** acetylcysteine
****** indication
severe cases e.g. cystic fibrosis
****** brand
Mucomyst
***** guaifenesin
****** brand
Robitussin
** pulmonary arterial hypertension (PAH)
*** epidemiology
- females disproportionately affected 1.7:1
- survival: 2.8 yrs without treatment
- typically diagnosed 20-50 yo
*** pathophysiology
- mean pulmonary artery pressure (mPAP) of ≥25 mm Hg
- left ventricular end diastolic pressure (LVEDP) ≤15 mm Hg
*** WHO classification
**** class 1
- No symptoms
- No limitation in ordinary physical activity
- Median survival: 6 years
***** recommended drug class
CCB (after a positive vasoreactivity test)
**** class 2
- Mild symptoms
- Slight limitation during ordinary activity
- Comfortable at rest
- Median survival: 6 years
***** recommended drug class
- Ambrisentan/bosentan/macitentan
- Sildenafil/tadalafil
- Riociguat
**** class 3
- Marked activity limitation due to symptoms at less-than-ordinary activity
- Comfortable ONLY at rest
- Median survival: 2.5 years
***** recommended drug class
- Bosentan/ambrisentan/macitentan
- Sildenafil/tadalafil
- Riociguat
If rapid progression or poor prognosis:
- IV epoprostenol
- IV, SubQ, or inhaled treprostinil
**** class 4
- Symptoms with any activity, even at rest
- Severe limitations
- Median survival: 6 months
***** recommended drug class
- IV epoprostenol
- IV or SubQ treprostinil
Patients unable to receive parenteral prostanoid therapy: Inhaled iloprost/treprostinil
*** diagnosis
**** diagnostic gold standard
/right heart catheterization/
**** vasoreactivity testing
***** short acting vasodilators :l:
****** epoprostenol
****** adenosine
****** nitric oxide
***** positive test criteria
reduction in mPAP of [10, 40) mm Hg /without decreasing CO/

Use CCBs for therapy if test is positive; do not use CCBs if negative.
***** contraindications
WHO FC IV symptoms
*** risk factors
- Drug/toxin induced
  - Fenfluramine
  - Amphetamines/Cocaine
  - Chemo (etoposide, bleomycin)
- Idiopathic vs. Familial
- Connective tissue diseases: Portal HTN, and HIV
- Pulmonary HTN of newborn
- Pulmonary venoocclusive disease
*** non-pharmacologic
- avoid pregnancy
- avoid high altitudes
- avoid decongestants/vasoconstrictors
- sodium restriction
- aerobic exercise
*** pharmacologic
**** gated behind drug access programs
- riociguat (Adempas)
- endothelial receptor antagonists
  - bosentan (Tracleer)
  - ambrisentan (Letairis)
  - macitentan (Opsumit)
**** digoxin
**** anticoagulation
**** CCBs
***** drugs
- nifedipine
- diltiazem
- amlodipine
***** contraindications
- LVEF <40%—LV systolic dysfunction
- negative vasoreactivity test
**** nitric oxide pathway :l:
***** sildenafil
****** brand
Reviato
****** dose
- 20-80 mg TID
- doses are greater for PAH than in ED
****** adverse effects
vision changes
***** tadalafil
****** brand
Adcirca
****** dose
- 20-40 mg QD
- doses are greater for PAH than in ED
***** riocigant
****** brand
Adempas
****** indication
chronic thromboembolic PH
**** endothelin receptor antagonists
- pregnancy category X
- requires drug access program
- hepatotoxic so measure LFTs
***** drugs :l:
****** bosentan
******* brand
Tracleer
****** ambrisentan
******* brand
Letairis
****** macitentan
******* brand
Opsumit
***** monitoring parameters :ignore:
LFTs
***** adverse effects :ignore:
potential serious liver injury
***** drug access :ignore:
requires restricted drug access program by pharmacy and prescriber because of its risks
***** warning :ignore:
- pregnancy category X; teratogenic
- decreases efficacy of oral contraceptives
**** prostacyclin pathway prostanoids
***** drugs :l:
****** epoprostenol
******* brand
- Flolan
- Veletri
******* ROA
- IV
- pump
****** treprostinil
******* brand
- Remodulin
- Tyvaso
- Orenitram
******* ROA
- SC
- IV
- pump
****** selexipag
******* brand
Uptravi
******* ROA
PO
****** iloprost
******* brand
Ventavis
******* ROA
inhaled; I-neb adaptive aerosol device
***** MOA
relaxes smooth muscle by increasing intracellular cAMP
